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Abstract
Background: There is accumulating evidence from immunological, pathological and therapeutic studies that B cells are key
components in the pathophysiology of multiple sclerosis (MS).
Methodology/Principal Findings: In this prospective study we have for the first time investigated the differences in the
inflammatory response between relapsing and progressive MS by comparing cerebrospinal fluid (CSF) cell profiles from
patients at the onset of the disease (clinically isolated syndrome, CIS), relapsing-remitting (RR) and chronic progressive (CP)
MS by flow cytometry. As controls we have used patients with other neurological diseases. We have found a statistically
significant accumulation of CSF mature B cells (CD19+CD1382) and plasma blasts (CD19+CD138+) in CIS and RRMS. Both B
cell populations were, however, not significantly increased in CPMS. Further, this accumulation of B cells correlated with
acute brain inflammation measured by magnetic resonance imaging and with inflammatory CSF parameters such as the
number of CSF leukocytes, intrathecal immunoglobulin M and G synthesis and intrathecal production of matrix
metalloproteinase (MMP)-9 and the B cell chemokine CxCL-13.
Conclusions: Our data support an important role of CSF B cells in acute brain inflammation in CIS and RRMS.
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Introduction
Multiple sclerosis (MS), a chronic inflammatory demyelinating
disease of the central nervous system (CNS), is generally assumed
to result from an autoimmune attack directed against the myelin
sheath [1]. The inflammatory reaction in the CNS of MS patients
involves various components of the immune system, including T
cells, B cells, macrophages but also antibodies and cytokines [2,3].
Several key findings implicate a pathogenic role of B cells and
antibodies in MS. Intrathecal immunoglobulin (Ig) synthesis and
oligoclonal bands are found in more than 90% of MS patients [4],
clonally expanded B cells accumulate in chronic MS lesions and in
the CSF of MS patients [5–10], antibody-mediated demyelination
was identified by histopathology [11,12] and B cell targeted
therapy has proven efficacy in phase II trials and open-label
studies in MS [13–15].
B cells are found in the cerebrospinal fluid (CSF) during CNS
inflammation, but are largelyabsentinnon-inflammatoryconditions
[16]. In acute infectious or chronic inflammatory neurological
diseases B cells may represent up to 30% of CSF cells [16–20]. In
contrast to the periphery, the majority of CSF B cells are CD27
expressing antigen-experienced memory B cells [17,20,21].
Although these studies have clearly shown an important role of
CSF B cells in CNS inflammation, their role in MS disease evolution
andprogressionislessclear.Newfocalwhitematterlesionsappearto
develop following new waves of inflammation, involving immune
cells which enter the brain from the peripheral blood and cause
major blood brain barrier (BBB) leakage mediated by matrix
metallproteinases (MMP). MMPs are supposed to be crucially
involved in the degradation of the extracellular matrix and to
facilitatesubsequentleukocyte recruitmentacrosscapillarybasement
membranes to the site of inflammation [22,23].
However, in contrast to early (relapsing-remitting) MS, the
further inflammatory reaction in progressive MS seems to be
compartmentalized within the CNS [24]. This is reflected by the
formation of aberrant lymphatic tissue within the connective tissue
compartments in the brain, the meninges and the perivascular
spaces [25]. These ectopic follicular B cell structures might be
crucial for a pathogenic and persisting B cell response driving
disease progression [26,27] and have been shown to contain B
cells, T cells, plasma cells and a network of follicular dendritic cells
producing homing lymphoid chemokines, such as CxCL-13 [25].
A recent study indicated that the intrathecal synthesis of CxCL-13
correlated with the number of CSF B cells [28].
We performed this prospective study to analyze CSF B cell
phenotypes from patients at the onset of the disease (clinically
isolated syndrome, CIS), relapsing-remitting (RR) and chronic
progressive (CP) MS with the aim to investigate whether patients/
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different B cell subpopulations correlate with different MS disease
courses and magnetic resonance imaging (MRI) characteristics,
and whether we may identify patients for stratification for B cell
focused treatment. In order to corroborate the involvement and
biological activities of B cells in this study population we also
analyzed MMP-9 and CxCL-13 in the CSF.
We report a statistically significant increase of CSF mature B
cells (CD19+CD1382) and plasma blasts (CD19+CD138+) in CIS
and RRMS. Further, this accumulation of B cells correlated with
acute brain inflammation measured by MRI and with inflamma-
tory CSF parameters such as the number of CSF leukocytes,




MS patients and neurological controls were recruited prospec-
tively from 2004 to 2008 at the Clinical Department of Neurology,
Innsbruck Medical University, Austria. This study was approved
by the ethical committee of Innsbruck Medical University (study
Nr. UN2045, 217/4.12, 07.07.2004) and all patients gave written
informed consent to the study protocol.
The following inclusion criteria had to be fulfilled by the group
of CIS and MS patients: (1) clinical symptoms meeting revised
‘‘McDonald Criteria’’ [29], (2) positive MRI findings according to
revised ‘‘McDonald Criteria’’ [29] and (3) presence of intrathecal
immunoglobulin synthesis (elevated Ig-indices and/or oligoclonal
IgG bands) [30]. 25 patients with a CIS, 20 patients with RRMS
and 8 patients with CPMS (2 with secondary progressive-SP and 6
with primary progressive-PP MS) were included. All MS patients
were diagnosed according to the established diagnostic criteria
[29,31] and a neurologist (A.L., R.E., C.G., T.B.) examined the
patients, including assessment of the expanded disability status
score (EDSS) and confirmation of relapse/disease progression
during the follow-up period. 3 patients received high-dose
corticosteroid treatment, whereas 3 patients received immuno-
modulatory treatments (2 patients received interferon-beta and
one patient received intravenous immunoglobulins) at the time of
lumbar puncture. 8 of 23 (31%) patients with a CIS converted to
clinically definite MS during the follow-up period of 12 months.
Demographic, clinical and CSF characteristics of all MS patients
and neurological controls are shown in Table 1.
The control group consisted of 30 patients with other
neurological diseases (OND). The OND group included 20
patients with noninflammatory OND (pseudotumor cerebri,
migraine, psychogenic neurological symptoms, sinus venous
thrombosis, cavernoma, vascular leukoencephalopathy, seizure,
herniated vertebral disc, transient ischemic attack, spastic
paraparesis, multiple system atrophy, neuropathic pain syndrome,
cerebellar infarction, brain tumor, focal dystonia, ischemic
transverse spinal cord syndrome) and 10 patients with inflamma-
tory OND (myelitis, ventriculitis, viral meningoencephalitis,
vasculitis, systemic lupus erythematosus, antiphospholipid syn-
drome, sarcoidosis and Guillain-Barre ´ syndrome).
Table 1. Demographic, clinical and CSF data of analyzed patients.
CIS RRMS CPMS OND p-value
n2 5 2 0 8 3 0
Females (%) 19 (76%) 16 (80%) 2 (25%) # 22 (73%) 0.02
2
Age (y)
1 26 (17–68) # 35 (15–63) 51 (36–63) 39 (21–74) 0.001
3
Duration (y)
1 0.1 (0.0–0.4) 4.9 (0.4–25.2) 7.8 (0.1–30.1) ,0.001
3
EDSS
1 2.0 (0.0–3.5) 2.0 (0.0–3.5) 5.8 (3.5–6.5) 0.001
3
Acute relapse 22 (88%) 14 (70%) 1 (13%) ,0.001
2
MRI Gd+ lesions 19 (76%) # 11 (55%) # 4 (50%) # 0/26 (0%) ,0.001
2
$9 MRI T2 lesions 9 (36%) # 6 (30%) # 3 (38%) # 0/26 (0%) 0.03
2
OCB 24 (96%) # 18 (90%) # 7 (88%) # 4/27 (15%) ,0.001
2
CSF cells/ml
1 10 (1–58) # 7 (1–32) # 4 (2–7) 1 (0–211) ,0.001
3
IgG index
1 0.8 (0.5–3.1) # 0.9 (0.4–2.0) # 0.7 (0.4–1.7) 0.5 (0.4–1.5) ,0.001
3
IgM index
1 0.2 (0.0–0.8) # 0.2 (0.1–0.5)# 0.2 (0.0–0.8) # 0.1 (0.0–0.5) ,0.001
3
Q-Alb




1 9 (1–468) # 8 (1–238) # 11 (1–94) # 1 (1–35) ,0.001
3
serum (pg/ml)
1 22 (1–177) 13 (1–80) 16 (1–104) 23 (1–302) ns
3
ratio




1 0.7 (0.0–21.4) # 0.5 (0.0–2.6) # 0.5 (0.0–0.8) 0.3 (0.0–99.8) 0.002
3
serum (ng/ml)
1 455 (180–1300) 435 (130–1798) 419 (223–777) 365 (79–1813) ns
3
ratio (61000)
1 1.6 (0.1–42.9) # 1.1 (0.0–7.8) 1.1 (0.1–3.5) 0.6 (0.0–396.9) 0.03
3
1 data are shown as median (range), p-value: groups were compared using 2 Qui-Square test or 3 Kruskal-Wallis test and Dunn’s multiple comparison post-hoc test, #
statistically significant different from OND control group.
Abbreviations: n=number of patients, y=years, EDSS=expanded disability status score, acute relapse=number of patients with an acute relapse, MRI Gd+
lesions=presence of gadolinium-enhancing lesions on T1-weighted MRI (neg=negative, pos=positive), $9 T2 MRI lesions=$9 lesions on T2-weighted MRI,
OCB=oligoclonal bands, Q-Alb=albumin quotient, MMP=matrix metalloproteinase, ratio=CSF:serum ratio, ns=statistically not significant.
doi:10.1371/journal.pone.0002559.t001
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CSF (3–8 ml), EDTA-treated whole blood and serum samples
(Sarstaedt Monovettes, Nuembrecht, Germany) were obtained
during standard diagnostic lumbar puncture and peripheral vein
puncture, respectively. CSF samples were immediately analyzed
for CSF cell populations within 30 minutes after lumbar puncture
and cell-free supernatants were stored at 280uC for further
diagnostic and scientific purposes. Serum was prepared by
centrifugation, 10 min at 3000 rpm, and stored at 220uC until
analysis was performed.
CSF samples were routinely analyzed for cell counts, quanti-
tative (IgM and IgG indices) and qualitative (oligoclonal bands)
analysis of intrathecal Ig-synthesis, and CSF to serum albumin
ratio (albumin-quotient) as indicators of the blood-brain barrier
status immediately after lumbar puncture using standard methods
(Table 1).
Characterization of CSF cell populations by flow
cytometry
Staining of CSF cells was done as recently described [16] with
the following modifications: CSF was immediately spun down after
lumbar puncture for 10 minutes at 1500 rpm. After removing the
supernatant, pellets were resuspended in 50 ml BD Cell-Wash (BD
Biosciences, San Jose, CA, USA) and CSF cells were stained with
fluorochrome-labeled antibodies to the following human leukocyte
surface antigens (all BD Biosciences) for a total of 30 minutes at
room temperature in the dark:
1) Mature B cells (CD19+CD1382), plasma blasts (CD19+CD138+)
and plasma cells (CD19-CD138+):5 ml CD-45 PerCP (BD
345809) 10 ml CD19-FITC (BD 245776) and 10 ml CD138-
PE (BD 347192).
2) B cells (CD19+) and T cells (CD3+):1 0ml TriTest CD45-
PerCP/CD3-FITC/CD19-PE (BD 342412).
Only when enough CSF cells were available the following
stainings were also included:
3) Monocytes:5ml CD-45 PerCP (BD 345809) 5 ml CD14-FITC
(BD 345784) and 5 ml HLA-DR-PE (BD 340689).
4) Natural killer cells:1 0ml TriTest CD45-PerCP/CD3-FITC/
CD16+56-PE (BD 342411).
5) Memory B cells:5ml CD-45 PerCP (BD 345809) 10 ml CD27-
FITC (BD 555440) and 10 ml CD19-PE (BD 345777).
Erythrocytes were lysed for 10 minutes using 2 ml of lysing
solution (BD Biosciences) according to manufacturer’s protocol.
Then, the tubes were centrifuged and the supernatants discarded.
After one additional washing step with 2 ml BD Cell-Wash, CSF
lymphocyte subpopulations were analyzed using three-color flow
cytometry on a BD FACScan with Cell Quest software (BD
Biosciences). Lymphocytes and monocytes were gated according
to their forward (FSC) and side scatter (SSC) properties. A
minimum number of 1000 events for each CSF staining was
acquired for analysis with lyse-wash instrument settings, threshold
FL-3 (PerCP) channel at 300 and the gate adjusted SSC versus FL-
3. Cell populations are shown in % of total lymphocytes.
Determination of CSF and serum levels of MMP-9 and
CxCL-13
CSF and serum concentrations of matrix metalloproteinase
(MMP)-9 (human MMP-9 DuoSet, DY911, R&D Systems,
Minneapolis, USA) and CxCL-13 (DuoSet human CXCL13/
BLC/BCA-1, Catalog No. DY801, R&D Systems, Minneapolis,
USA) were measured with commercially available enzyme-linked
immunosorbent assays (ELISA) according to manufacturer’s
protocol. CSF samples were analyzed at a dilution of 1:51 (for
MMP-9) and undiluted (for CxCL-13). Serum samples were
analyzed at a dilution of 1:1501 (for MMP-9) and 1:3 (for CxCL-
13). In order to correct for a passive transfer of MMP-9 and
CxCL-13 we calculated a ratio using the following formula: MMP-
9 ratio=MMP-9 CSF/MMP-9 Serum.
MRI protocol
All MS patients and 26 of 30 OND patients were examined by a
standardized brain MRI protocol (duration about 18 min) at the
time of diagnostic lumbar puncture. Patients were scanned on a
1.5 T whole-body MR scanner (Magnetom Avanto, Siemens,
Germany) using the following protocol:
1) Coronal MPRage (repetition time (TR) 1600 ms, Inversion
time (TI) 800 ms, echotime (TE) 3.44 ms, matrix 2566224,
field of view 2306193 mm, slice thickness of 1.2 mm,
number of excitations 1, iPAT factor 2)
2) Transversal diffusion tensor imaging by using a EPI
sequence (TR 6000 ms, TE 94 ms, matrix 1286128
interpolated to 2566256, field of view 2206220 mm, slice
thickness of 3 mm, 35 slices, iPAT factor 2, diffusion-
sensitizing gradients in six directions)
3) Sagittal SPACE 3D with darkfluid preparation (TR
6000 ms, TI 2200 ms, TE 328 ms, matrix 2566236, field
of view 2406221 mm, slice thickness 0.9 mm)
4) Pause of at least five minutes after administration of contrast
agent (Gadolinium-DTPA)
5) Repetition of sequence 1
Statistical analysis
Statistical analysis (means, medians, range, standard deviations),
significance of group differences and linear regression were
evaluated using SPSS software (release 14.0, SPSS Inc., USA)
and GraphPad Prism 5 (GraphPad, San Diego, USA). The
distribution of groups was determined via Kolmogorov-Smirnov
test. Between-group comparisons were performed with Kruskal-
Wallis test, Dunn’s multiple comparison post-hoc test, Mann-
Whitney U test, Fisher’s exact test and Qui-square test.
Correlation of parameters was analyzed with Spearman’s non-
parametric correlation. Statistical significance was defined as two-
sided p-value,0.05 and Bonferroni corrections were made for
multiple comparisons when appropriate.
Results
The frequency/percentage of CSF B cells is increased in
acute CNS inflammation
CSF samples were analyzed for the presence of B cells by flow
cytometry. During acquisition, lymphocytes were gated according to
CD45-PerCP staining and SSC properties and subsequent analysis
was done using their FSC versus SSC properties (Figure 1A).
The percentage of T cells and B cells within CSF was measured
in each specimen using monoclonal antibodies to CD3 and CD19.
Whereas T cells were present in all samples, B cells were barely
detectable in the CSF of OND patients, but present in almost all
patients with CIS, RRMS and CPMS (Figure 1B-E). CSF B cells
were then characterized by a combination of CD19 and CD138
stainings (Figure 1B–E). While the vast majority of all CSF B cells
were CD19+CD1382 mature B cells (range 0–12.4%) and
CSF B Cells in MS
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number of CSF cells had the CD192CD138+ phenotype of long-
lived plasma cells (range 0–1.3%). Additional stainings, which were
however only possible in a few MS patients (due to limited CSF
amounts), indicated that the majority of CSF B cells belong to the
CD19+CD27+ memory B cell subset, while only a minority are
naı ¨ve CD19+CD272 B cells (data not shown). In consistence with
previous reports [16,17,20] we never found CD19+CD138+ plasma
blasts in the peripheral blood of MS patients (data not shown).
From Figure 2A it is evident that most of the lymphocytes
present in CSF samples are T cells (range 63.8–96.9%), but
without significant differences between different MS disease
courses and OND (p=0.11). In contrast, CSF CD19+CD1382
Figure 1. CSF B cell subsets. (A) Dot plots of CSF leucocytes
according to their CD45-PerCP versus side scatter properties (left panel)
and forward versus side scatter properties (right panel). Region 1 (R1,
left panel) was used for acquisition of a minimum number of 1000
events and region 2 (R2, right panel) was used for analysis. CSF analysis
of representative patients with a CIS (B), RRMS (C), CPMS (D) and OND
(E) for the presence of CD3+ T cells and CD19+ B cells (left panel), and
CD19+CD1382 mature B cells, CD19+CD138+ plasma blasts and
CD192CD138+ plasma cells (right panel). The numbers represent the
relative percentages of these cell populations.
doi:10.1371/journal.pone.0002559.g001
Figure 2. Percentages of CD3+ T cells (A), CD19+CD1382
mature B cells (B) and CD19+CD138+ plasma blasts (C) in the
CSF of patients with a CIS, RRMS, CPMS and OND. Individual data
points are shown as circles and horizontal bars indicate means. Data
were compared using the Kruskal-Wallis test and Dunn’s multiple
comparison post-hoc test and overall p-values are shown in each figure.
#=significant differences to the OND group.
doi:10.1371/journal.pone.0002559.g002
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cantly increased in CIS and RRMS as compared to OND
(p,0.001, Figure 2 B and C). Neither mature B cells nor plasma
blasts were significantly increased in CPMS. Within OND patients
CSF CD19+CD1382 mature B cells and CD19+CD138+ plasma
blasts were only detectable in some patients with inflammatory
OND (myelitis and systemic lupus erythematosus).
As mentioned above CD192CD138+ long-lived plasma cells
were nearly absent in all disease groups and no significant
differences were found between groups. Further, we found no
statistical significances in the frequencies of natural killer cells
(n=83) and monocytes (n=46) between the groups analyzed.
Within MS patients CSF mature B cell, but not plasma blast,
counts were significantly higher in CIS and RRMS than in CPMS
(p=0.028). Within CPMS, patients with SPMS (n=2) had higher
CSF CD19+CD1382 and CD19+CD138+ counts than PPMS
(n=6, p=0.046). Further, CSF CD19+CD1382 mature B cells
were significantly increased (p=0.01) in patients with an acute
relapse (median 3.9, range 1.1–12.4%) as compared to patients in
remission (median 2.3, range 0.6–6.8%) and progression (median
1.5, range 0.1–6.2%). No significant differences were found for T
cells, plasma blasts and other CSF cell populations. CSF T cells,
mature B cells and plasma blasts did not significantly correlate
with other clinical parameters such as age, gender, disease
duration, EDSS and conversion to clinically definite MS.
CSF B cells correlate with paraclinical markers of CNS
inflammation
We next analyzed whether CSF cell populations correlate with
MRI activity, defined by the number of lesions on T2-weighted
MRI (2 groups: ,9 and $9 T2 lesions) and the presence of Gd-
enhancing lesions on T1-weighted MRI (2 groups: Gd-enhancing
lesions present or not) at the time point of CSF sampling. As
shown in Table 2, CSF mature B cells and plasma blasts were
highly significantly associated with a higher disease activity on
MRI measured by the presence of numerous ($9) T2 lesions and
the presence of Gd-enhancing lesions, indicating an acute
inflammatory reaction within the CNS and concomitant blood-
brain barrier dysfunction. This association with MRI parameters
was also seen for higher total numbers of CSF cells with the
presence of Gd-enhancing lesions (median 8.5, range 2.3–58.0
versus median 2.7, range 0.3–210.7 cells/ml, p,0.001), but not for
MRI T2 lesions. CSF T cells, NK cells and monocytes were,
however, not correlated with MRI parameters.
CSF mature B cells and plasma blasts were also highly
significantly correlated with other inflammatory CSF parameters,
such as CSF leukocyte counts and intrathecal IgM and IgG
synthesis measured by IgM and IgG indices and positive
oligoclonal bands (Table 2). Further, both CSF mature B cells
and plasma blasts were negatively correlated with CSF CD3+
cells, whereas we found no significant correlation with CSF
CD56+ NK cells and CD14+ monocytes.
From Table 1 it is evident that CSF, but not serum, CxCL-13
levels were significantly increased in CIS, RRMS and CPMS.
Further, CSF and serum CxCL-13 levels of patients with CIS,
RRMS and CPMS had similar ranges and also CSF:serum ratios
were significantly increased in these patients. Both, CSF CxCL-13
levels and CxCL-13 CSF:serum ratios showed a highly significant
correlation with CSF mature B cells and plasma blasts (Table 2).
From Table 1 it is also evident that CSF levels of MMP-9, but
not serum levels, were significantly increased in CIS and RRMS,
and the CSF:serum ratio was also increased in CIS. Further, CSF
MMP-9 levels were higher (p=0.04) in patients with an acute
relapse (median 0.6, range 0.0–5.7 ng/ml) than in remission
(median 0.3, range 0.1–1.5 ng/ml) or progression (median 0.5,
range 0.0–0.8 ng/ml). CSF MMP-9 levels (median 0.3, range 0.0–
1.0 versus median 0.6, range 0.0–5.2 ng/ml, p,0.001) and
CSF:serum ratios (median 0.6, range 0.0–2.5 versus median 1.6,
range 0.0–31.6, p,0.001) were also significantly increased in
patients with Gd-enhancing MRI lesions and showed a highly
significant correlation with CSF mature B cells and plasma blasts
(Table 2). This significant correlation of CSF MMP-9 levels
(R=0.622, p,0.001) and CSF:serum ratios (R=0.483, p,0.001)
was also seen for the total number of CSF cells, but not for CSF T
cells, NK cells and monocytes.
Discussion
Our prospective study was designed to compare the B cell
inflammatory response between relapsing and progressive MS by
characterizing the CSF cell profiles from patients at the onset of
the disease (CIS), RRMS, CPMS and OND. Our data clearly










1 1.1 (0.1–12.4) 0.3 (0.0–5.2)
MRI Gd pos
1 3.3 (0.6–9.4) 1.1 (0.0–7.1)




1: 1.1 (0.1–12.4) 0.3 (0.0–5.2)
$9 lesions
1: 3.3 (0.6–9.4) 1.1 (0.0–7.1)
CSF CD19+CD1382 cells R=0.650, p,0.001
3
CSF CD19+CD138+ cells R=0.650, p,0.001
3
CSF CD3+ cells R=20.561, p,0.001
3 R=20.395, p,0.001
3
CSF CD56+ cells R=20.275, ns R=20.199, ns
CSF CD14+ cells R=20.150, ns R=20.209, ns
CSF cells/ml R=0.550, p,0.001
3 R=0.443, p,0.001
3
Q-Alb R=20.136, ns R=20.052, ns
IgM index R=0.488, p,0.001
3 R=0.585, p,0.001
3







1 0.7 (0.2–9.4) 0.2 (0.0–1.7)
OCB pos
1 2.9 (0.1–12.4) 1.0 (0.0–7.1)
CxCL-13:
CSF (pg/ml) R=0.574, p,0.001
3 R=0.522, p,0.001
3




CSF (ng/ml) R=0.415, p,0.001
3 R=0.440, p,0.001
3






1 data are shown as median (range), p-value: groups were compared using 2
Mann-Whitney U test or 3 Spearmans nonparametric correlations.
Abbreviations: MRI Gd+ lesions=presence of gadolinium-enhancing lesions on
T1-weighted MRI (neg=negative, pos=positive), MRI T2 lesions=number of
lesions on T2-weighted MRI, Q-Alb=albumin quotient, OCB=oligoclonal
bands, MMP=matrix metalloproteinase, R=Spearman’s correlation coefficient,
ns=statistically not significant.
doi:10.1371/journal.pone.0002559.t002
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is clearly more pronounced in acute inflammation, i.e. CIS and
RRMS, than in CPMS and OND. The majority of these B cells
showed the expression pattern of mature B cells (phenotype:
CD19+CD1382), which have the ability to remain in the CNS
compartment for years [17]. We have also observed an increased
frequency of CD19+CD138+ plasma blasts in CIS and RRMS,
but not in CPMS and OND. In contrast, only a scant amount of
long-lived plasma cells (phenotype: CD192CD138+) was detected
in the CSF. Consistently, a predominance of mature B cells and
short-lived plasma blasts in CSF of patients with MS and acute
neuroinfection has been reported previously [16–19,21]. By
contrast, a recent report also showed increased number of
CD192CD138+ plasma cells in the CSF of patients with
neuroinflammatory diseases [20].
Our finding that CSF B cells are correlated with other
paraclinical markers of acute brain inflammation such as high
numbers of MRI T2 lesions, the presence of Gd-enhancing MRI
lesions, total number of CSF cells, intrathecal IgM and IgG
synthesis and intrathecal MMP-9 and CxCL-13 production
indicate a direct involvement of B cells in acute brain
inflammation. These findings might also explain some of the
dramatic effects seen in recent therapeutic trials in RRMS
patients. Natalizumab, a recently re-approved drug for MS
treatment, has been shown to reduce the numbers of CD19+ B
cells and CD138+ plasma cells within the CSF [32] which
correlated with the reduction of relapse rates as well as of the
inflammatory disease activity on MRI. Similar effects were
observed with rituximab, a monoclonal antibody selectively
depleting CD20+ B cells [13–15], thus indicating an influence of
B cells on disease pathogenesis and ongoing immune responses.
Although B cell targeted therapy has proven efficacy in RRMS
patients and clinical trials in CPMS patients are ongoing, we do
not yet know which patients could most probably benefit from a B
cell targeted therapy. It is thus tempting to speculate whether the
CSF B cell profile might be helpful in identifying patients that
might benefit from these treatments.
Despite the difference seen in the frequency of CSF B cells
between RRMS and CPMS, humoral factors like IgM, IgG and
CxCL-13 were found at increased levels in all MS subgroups thus
raising the question on their source. Recent studies indicated that
the continuous maturation of memory B cells into plasma blasts,
driven by disease-associated antigens, might proceed in meningeal
germinal centre-like structures within the CNS [25,27,33]. Since
the ectopic expression of CxCL-13 is considered to promote the
formation of lymphoid-like structures [34] its expression in MS
lesion might have similar effects in this disease [25,35]. Further, in
a recent study a strong correlation between CxCL-13 levels and
inflammatory activity in MS was observed, which was reflected by
an upregulation of CxCL-13 in actively demyelinating MS lesions
and increased CxCL-13 in the CSF [28]. Thus the chemokine
CxCL-13 might play a critical role in organizing immune
responses within CNS by providing favorable microenvironmental
preconditions for compartmentalizing B cell response and
sustaining a chronic inflammatory process in the CNS. The lower
frequencies of mature B cells and plasma blasts in CPMS, as well
as the absence of CD19-CD138+ long-lived plasma cells in the
CSF observed in our study and by others [16,17], could thus
reflect the retaining of this cell subset within germinal centers in
the meninges.
In our study we found a significant correlation of CSF MMP-9
levels and CSF:serum ratios with the number of mature B cells and
plasma blasts, but not with any other cell type. Further, CSF
MMP-9 levels were increased in CIS, in patients with an acute
relapse and in patients with Gd-enhancing MRI lesions thus
confirming previous results [36,37]. Our finding that the
correlations between CSF cell populations and intrathecal
MMP-9 production were restricted to B cell subsets may either
indicate that B cells are responsible for the release of MMP-9
[38,39] or that the MMP-9 release facilitates, amongst other
molecules, B cell migration through the BBB.
In conclusion the results of our study reveal an accumulation of
mature B cells and plasma blasts in the CSF of patients with a CIS
and RRMS, which is associated with an increased intrathecal CSF
cell count and MMP-9, CxCL-13, IgG and IgM synthesis.
Although the specificity of these intrathecal B cells is not known
and the role of antibodies in the immunopathogenesis of MS is still
unclear, the findings of this study confirm a role of B cells and
humoral factors in MS disease activity. Because the core phase of
our study has been scheduled for a maximum of 3 years at study
initiation, an extension phase is now planned in order to collect
follow-up clinical data of the study cohort (progression index, time
to conversion to clinically definite and chronic-progressive MS).
These studies will hopefully clarify the implications of different
CSF cell subsets for prognosis and potentially add information to
the decision process of therapeutic strategies in MS.
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